A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Center for Biomedicine and Genetics Bookmark and Share

Center for Biomedicine and Genetics

City of Hope established the Center for Biomedicine and Genetics (CBG) to ensure that its technological innovations are efficiently translated from the research lab to the clinical setting in a cost-effective and expeditious manner.  The center also allows scientific and clinical investigators the freedom to test and refine the most promising new therapeutics. 
 
  • CBG is recognized as the nation's premier academic biologic manufacturing facility (the “gold standard” for such facilities, according to the Food and Drug Administration), and has been lauded by The New York Times for its leading role in devising innovative methods of rapid drug development.
     
  • CBG was founded with generous support from City of Hope’s  National Office Products Industry (NOPI), and is licensed by the state and federal government to produce pharmaceutical-grade therapeutic compounds.
     
  • CBG provides investigators with the isolation, environmental control and security needed for the manufacture of products for human use. It functions as a centralized facility and shared resource, available for multiple investigators both on and off campus.
  • CBG is a founding member of the Association of Academic Biologics Manufacturers (AABM), whose mission is to establish a cooperative network of nonprofit, academic-based biologics manufacturers. The association serves as a national resource that brings together clinical investigators with manufacturing capacity and expertise, develops and shares facility operations knowledge among members, provides quality, manufacturing and regulatory training opportunities, and holds annual meetings.
 
GMP-grade Biologics Production
CBG is designed specifically to accommodate small scale (bench-top) production of GMP-grade biologics, viral and nonviral gene therapeutics and modified patient cell populations to support phase I and II clinical trials at City of Hope.  Adherence to cGMP (current Good Manufacturing Practices) is essential in ensuring the quality and integrity of manufactured biologics.
 
Islet Cell Production
The islet cell production facility at CBG provides isolated islet cells for the islet cell resource centers, which are accelerating the study of islet cell transplantation as a potential cure for type 1 diabetes.
 
Partnership Opportunities
An important component of CBG is our Production Partnership Program, which facilitates the development of innovative biologics created by City of Hope investigators, colleagues and partners to treat patients with cancer, diabetes, viral disease and other life-threatening illnesses, and establishes working relationships with regional biopharmaceutical and academic organizations.

The regulatory expertise and manufacturing skill consistently demonstrated by CBG, coupled with leading-edge bioinformatics and clinical trials groups, makes City of Hope an attractive partner for companies looking to streamline drug development and bring exciting new therapeutic technologies to our patients.
 

About Our Facility

CBG’s two-story, 20,000 square-foot, state-of-the-art secured building features:
 
  • 10,000 square feet of biologics manufacturing space (clean rooms) in three specialized zones:
     
  • Viral vector zone – processes in development include adenovirus, retrovirus, adeno-associated virus, lentivirus
  • DNA and protein production zone – 13 production and purification suites served by dedicated aseptic fill-and-finish with air-handling system for class 100/1000 sterile materials, equipment, glassware autoclave/glasswasher and quarantine areas
  • Cell engineering zone – processes in development include ex vivo T-cell and islet cell manipulation

These zones have separate entries, gowning, air-handling and exits to ensure complete isolation of simultaneous production processes.
  • Water facilities: clinical-grade water generator system (2,000 gallon/day capacity); water for injection steam generator for sterilization
  • Cryogenics storage rooms
  • Irradiator facilities
  • Four-gas storage system
  • Quality Control, Quality Assurance and product release storage and management

In addition, this facility supports phase I and II clinical trials at City of Hope through pilot-scale cGMP (current Good Manufacturing Practices) production of:
 
  • Biologics
  • Viral and nonviral gene therapeutics
  • Modified patient cell populations

The design of the facility allows for these three processes to be performed simultaneously, under cGMP, in functionally isolated areas of the building. Further important features include:
 
  • WFI clean stream
  • BL-3 containment capability
  • Key-card-restricted access
  • Provisions for CO2, medical grade air, N2 or other gases
  • Validated monitoring of all equipment, including HVAC and pressurization equipment

Technological Expertise
While CBG is designed to accommodate a wide variety of biological production and purification processes, specific expertise exists in the following areas:
 
  • AAV/adenovirus and retrovirus production 
  • Plasmid DNA production
  • Monoclonal antibody production
  • Hematopoietic cell purification, transduction and propagation
 

Center for Biomedicine & Genetics

Center for Biomedicine and Genetics

Center for Biomedicine and Genetics

City of Hope established the Center for Biomedicine and Genetics (CBG) to ensure that its technological innovations are efficiently translated from the research lab to the clinical setting in a cost-effective and expeditious manner.  The center also allows scientific and clinical investigators the freedom to test and refine the most promising new therapeutics. 
 
  • CBG is recognized as the nation's premier academic biologic manufacturing facility (the “gold standard” for such facilities, according to the Food and Drug Administration), and has been lauded by The New York Times for its leading role in devising innovative methods of rapid drug development.
     
  • CBG was founded with generous support from City of Hope’s  National Office Products Industry (NOPI), and is licensed by the state and federal government to produce pharmaceutical-grade therapeutic compounds.
     
  • CBG provides investigators with the isolation, environmental control and security needed for the manufacture of products for human use. It functions as a centralized facility and shared resource, available for multiple investigators both on and off campus.
  • CBG is a founding member of the Association of Academic Biologics Manufacturers (AABM), whose mission is to establish a cooperative network of nonprofit, academic-based biologics manufacturers. The association serves as a national resource that brings together clinical investigators with manufacturing capacity and expertise, develops and shares facility operations knowledge among members, provides quality, manufacturing and regulatory training opportunities, and holds annual meetings.
 
GMP-grade Biologics Production
CBG is designed specifically to accommodate small scale (bench-top) production of GMP-grade biologics, viral and nonviral gene therapeutics and modified patient cell populations to support phase I and II clinical trials at City of Hope.  Adherence to cGMP (current Good Manufacturing Practices) is essential in ensuring the quality and integrity of manufactured biologics.
 
Islet Cell Production
The islet cell production facility at CBG provides isolated islet cells for the islet cell resource centers, which are accelerating the study of islet cell transplantation as a potential cure for type 1 diabetes.
 
Partnership Opportunities
An important component of CBG is our Production Partnership Program, which facilitates the development of innovative biologics created by City of Hope investigators, colleagues and partners to treat patients with cancer, diabetes, viral disease and other life-threatening illnesses, and establishes working relationships with regional biopharmaceutical and academic organizations.

The regulatory expertise and manufacturing skill consistently demonstrated by CBG, coupled with leading-edge bioinformatics and clinical trials groups, makes City of Hope an attractive partner for companies looking to streamline drug development and bring exciting new therapeutic technologies to our patients.
 

About Our Facility

About Our Facility

CBG’s two-story, 20,000 square-foot, state-of-the-art secured building features:
 
  • 10,000 square feet of biologics manufacturing space (clean rooms) in three specialized zones:
     
  • Viral vector zone – processes in development include adenovirus, retrovirus, adeno-associated virus, lentivirus
  • DNA and protein production zone – 13 production and purification suites served by dedicated aseptic fill-and-finish with air-handling system for class 100/1000 sterile materials, equipment, glassware autoclave/glasswasher and quarantine areas
  • Cell engineering zone – processes in development include ex vivo T-cell and islet cell manipulation

These zones have separate entries, gowning, air-handling and exits to ensure complete isolation of simultaneous production processes.
  • Water facilities: clinical-grade water generator system (2,000 gallon/day capacity); water for injection steam generator for sterilization
  • Cryogenics storage rooms
  • Irradiator facilities
  • Four-gas storage system
  • Quality Control, Quality Assurance and product release storage and management

In addition, this facility supports phase I and II clinical trials at City of Hope through pilot-scale cGMP (current Good Manufacturing Practices) production of:
 
  • Biologics
  • Viral and nonviral gene therapeutics
  • Modified patient cell populations

The design of the facility allows for these three processes to be performed simultaneously, under cGMP, in functionally isolated areas of the building. Further important features include:
 
  • WFI clean stream
  • BL-3 containment capability
  • Key-card-restricted access
  • Provisions for CO2, medical grade air, N2 or other gases
  • Validated monitoring of all equipment, including HVAC and pressurization equipment

Technological Expertise
While CBG is designed to accommodate a wide variety of biological production and purification processes, specific expertise exists in the following areas:
 
  • AAV/adenovirus and retrovirus production 
  • Plasmid DNA production
  • Monoclonal antibody production
  • Hematopoietic cell purification, transduction and propagation
 

Meet our Staff

Center for Biomedicine & Genetics

Contact Us
For inquiries concerning the CBG manufacturing facility and collaborative opportunities please contact:
 
Larry A. Couture, Ph.D. or
David Hsu, Ph.D.
Center for Applied Technology Development
City of Hope
1500 E. Duarte Road
Duarte, CA 91010
626-256-8728
Center for Applied Technology Development (CATD)
The Sylvia R. and Isador A. Deutch Center for Applied Technology Development (CATD) offers broad expertise in technology transfer and licensing, biologics manufacturing, quality assurance and regulatory affairs.

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.


NEWS & UPDATES
  • Equipping the immune system to fight cancer – a disease that thrives on mutations and circumventing the body’s natural defenses – is within reach. In fact, City of Hope researchers are testing one approach in clinical trials now. Scientists take a number of steps to turn cancer patients’ T cells – white b...
  • As treatments for lung cancer become more targeted and effective, the need for better technology to detect lung cancer mutations becomes increasingly important. A new clinical study at City of Hope is examining the feasibility of using blood and urine tests to detect lung cancer mutations, potentially allowing ...
  • When it comes to breast cancer risk, insulin levels may matter more than weight, new research has found. The study from Imperial College London School of Public Health, published in the journal Cancer Research, indicates that metabolic health – not a person’s weight or body mass index – increases breast cancer ...
  • No one ever plans to have cancer – and there’s never a good time. For Homa Sadat, her cancer came at a particularly bad time: just one year after losing her father to the pancreatic cancer he had battled for two years. She was working a grueling schedule managing three commercial office buildings. She’d just [&...
  • Patients at City of Hope – most of whom are fighting cancer – rely on more than 37,000 units of blood and platelets each year for their treatment and survival. Every one of those units comes from family, friends or someone who traded an hour or so of their time and a pint of their […]
  • Surgery is vital in the treatment of cancer – it’s used to help diagnose, treat and even prevent the disease – so a new colorectal cancer study linking a decrease in surgeries for advanced cancer to increased survival rates may raise more questions than it answers for some patients. The surgery-and-surviv...
  • Age is the single greatest risk factor overall for cancer; our chances of developing the disease rise steeply after age 50. For geriatric oncology nurse Peggy Burhenn, the meaning is clear: Cancer is primarily a geriatric condition. That’s why she is forging inroads in the care of older adults with cancer. Burh...
  • One of American’s great sportscasters, Stuart Scott, passed away from recurrent cancer of the appendix at the young age of 49. His cancer was diagnosed when he was only 40 years old. It was found during an operation for appendicitis. His courageous fight against this disease began in 2007, resumed again with an...
  • When Homa Sadat found a lump in her breast at age 27, her gynecologist told her what many doctors say to young women: You’re too young to have breast cancer. With the lump dismissed as a harmless cyst, she didn’t think about it again until she was at a restaurant six months later and felt […]
  • What most people call a “bone marrow transplant” is not actually a transplant of bone marrow; it is instead the transplantation of what’s known as hematopoietic stem cells. Such cells are often taken from bone marrow, but not always. Hematopoietic stem cells are simply immature cells that can ...
  • Doctors have long known that women with a precancerous condition called atypical hyperplasia have an elevated risk of breast cancer. Now a new study has found that the risk is more serious than previously thought. Hyperplasia itself is an overgrowth of cells; atypical hyperplasia is an overgrowth in a distorted...
  • Don’t kid yourself. Just because it’s mid-January doesn’t mean it’s too late to make resolutions for a happier, and healthier, 2015. Just consider them resolutions that are more mature than those giddy, sometimes self-deluded, Jan. 1 resolutions. To that end, we share some advice from Cary A. Presant, M.D., an ...
  • Sales and marketing executive Jim Murphy first came to City of Hope in 2002 to donate blood for a friend who was being treated for esophageal cancer. The disease is serious. Although esophageal cancer accounts for only about 1 percent of cancer diagnoses in the U.S., only about 20 percent of patients survive at...
  • Aaron Bomar and his family were celebrating his daughter’s 33rd birthday in September 2014 when he received alarming news: According to an X-ray taken earlier that day at an urgent care facility, he had a node on his aorta and was in danger of an aneurysm. Bomar held hands with his wife and daughter and s...
  • Explaining a prostate cancer diagnosis to a young child can be difficult — especially when the cancer is incurable. But conveying the need for prostate cancer research, as it turns out, is easily done. And that leads to action. Earlier this year, Gerald Rustad, 71, who is living with a very aggressive form of m...